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Purpose. We sought to develop nanoscale drug delivery materials
that would allow targeted intracellular delivery while having an im-
aging capability for tracking uptake of the material. A complex na-
nodevice was designed and synthesized that targets tumor cells
through the folate receptor.
Methods. The device is based on an ethylenediamine core polyami-
doamine dendrimer of generation 5. Folic acid, fluorescein, and
methotrexate were covalently attached to the surface to provide tar-
geting, imaging, and intracellular drug delivery capabilities. Molecu-
lar modeling determined the optimal dendrimer surface modification
for the function of the device and suggested a surface modification
that improved targeting.
Results. Three nanodevices were synthesized. Experimental targeting
data in KB cells confirmed the modeling predictions of specific and
highly selective binding. Targeted delivery improved the cytotoxic
response of the cells to methotrexate 100-fold over free drug.
Conclusions. These results demonstrate the ability to design and pro-
duce polymer-based nanodevices for the intracellular targeting of
drugs, imaging agents, and other materials.
KEY WORDS: dendrimer; nanotechnology; chemotherapeutic mo-
lecular modeling; methotrexate.
INTRODUCTION
Folic acid (FA) is internalized into cells through a high
affinity, receptor-mediated process (1). FA-conjugated pro-
teins, such as RNase, BSA, IgG, and ferritin are also taken
into cells through the folate-receptor pathway in a nonde-
structive manner (2,3). Because the high affinity FA receptor
is overexpressed in several human cancer cells (4,5,6), relative
tumor selective targeting has been achieved with FA-
conjugated antineoplastic drugs (7), antisense oligonucleo-
tides (8), protein toxins (9), and imaging agents (10). How-
ever, the direct conjugation of folate to the bioactive molecule
can lead to loss of targeting or alter the function of the con-
jugate, and most of the conjugates cannot be further modified
to improve targeting or anti-tumor activity (2–10).
Polyamidoamine (PAMAM) dendrimers are highly
branched macromolecules with well-defined architecture (11)
that can serve as a unique platform for a variety of therapeu-
tic and imaging agents (12–17). We have developed den-
drimer-based nanodevices optimized to target complex thera-
peutics. This involved computer modeling of the nanodevices
in the hydrated state to find modifications of the primary
amine groups that would optimize targeting. From the mod-
eling studies, we synthesized modified polymers and evalu-
ated their uptake and internalization in tumor cells that over-
express the high affinity folate receptor. The behavior of
these dendrimer nanodevices was in accordance with the
modeling predictions indicating the potential for these de-
vices to be computer designed.
MATERIALS AND METHODS
Materials and Reagents
FA, acetic acid, dimethylsulfoxide (DMSO), penicillin/
streptomycin, fetal bovine calf serum (FBS), and bovine se-
rum albumin (BSA) were purchased from Sigma (St. Louis,
MO, USA). Trypsin-EDTA, Dulbecco’s phosphate buffered
saline (PBS), and RPMI 1640 medium (with or without FA)
were obtained from Gibco/BRL (Gaithersburg, MD, USA).
Synthesis Procedures and Analysis
Folate/Fluorescein Dendrimer
Generation 5 PAMAM dendrimer was prepared and
analyzed as described previously (18). Dendrimer (50 mg,
1.70 mol) was dissolved in DMSO (2 mL) and sodium phos-
phate buffer (0.1 M, pH 9, 5 mL) under nitrogen for conju-
gation to fluorescein isothiocyanate (17.3 mg, 44 mol, 0.2
equivalents per dendrimer primary amine). The mixture was
stirred in the dark for approximately 24 h, then washed and
ultrafiltered in Centricon tubes (10,000 MWCO; Amicon).
Folate was conjugated to the dendrimer through an EDC
linkage as described (15).
Acetamide and 2,3-Hydroxypropyl Capping of Dendrimers
A solution of the dendrimer (1.70 mol) in 8 mL of 1:1
DMSO:0.1 M sodium phosphate buffer (pH 9) was prepared.
The following was repeated four times: acetic anhydride (79
L, 833 mol per day) was added dropwise, stirred for several
hours; the pH of the solution was adjusted back to nine, and
then stirred overnight in the dark under nitrogen. On the fifth
day, the small amount of white precipitate was removed by
filtration through Celite. The orange filtrate was purified by
exhaustive dialysis against deionized water, using a 10,000
MWCO membrane (Spectrum Medical Industries). The re-
tentate was concentrated by rotary evaporation to produce
50.8 mg of orange solid. 2, 3-Hydroxypropyl was prepared in
the same manner but with the addition of glycidol (110 L per
day) in place of acetic anhydride.
Carboxyl and Fluorescein-Carboxyl Capped Dendrimer
To a solution of succinic anhydride (18 mg; 179 mol) in
dry DMSO, dendrimer (50 mg; 1.2 mol) in DMSO was
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added dropwise, then stirred at ambient temperature under
an atmosphere of nitrogen in dark for 18h. The reaction mix-
ture was diluted with water and dialyzed in deionized water
using a 1000 MWCO regenerated cellulose dialysis mem-
brane. The retentate was then concentrated in vacuo and ly-
ophilized to give the acid-capped dendrimer conjugate.
Analysis of the 1H NMR spectrum integration showed that
there was an average of 16 fluorescein and 2.5 folate moieties
per dendrimer conjugate.
Methotrexate Conjugation with an Amide or Ester Bond
In 3 mL of DMF and 1 mL of DMSO solvent mixture, 0.5
mg methotrexate (9.9 × 10−7mol) and 2.6 mg of 1-[3-
(Dimethylamino) propyl-3-ethylcarbodiimide hydrochloride
(1.4 × 10−5 mol) were added. The mixture was allowed to
react for 1 h at room temperature under nitrogen, with vig-
orous stirring. The methotrexate active ester was added drop-
wise into the 3.4 mg (9.9 × 10−8 mol) bifunctional dendrimer
[G5-Ac(96)-FITC(5)-FA(3)] in 12 mL DI water. The reaction
mixture was stirred at room temperature for 3 days and the
G5-Ac96-FITC5-FA3-MTX4 formed was dialyzed and lyoph-
ilized. The ester linkage was developed similarly by adding
methotrexate active ester to 5.5 mg (1.6 × 10−7mol) of bifunc-
tional dendrimer with hydroxyl surface
Theoretical Modeling of Conjugated Dendrimer Devices
Model building and molecular dynamics simulations
were performed on an Onyx workstation (Silicon Graphics,
Inc.; Mountain View, CA, USA) using the Insight II software
package (Molecular Simulations Inc.; San Diego, CA, USA).
A generation 5 PAMAM dendrimer (EDA core) was first
built and simulated with the consistent valence force field
(CVFF) (10) for 50 ps at 295 °K, after standard minimization
and annealing processes. The primary amines of a PAMAM
dendrimer were all protonated to simulate pH 7 conditions. A
distance-dependent dielectric constant was used to shield
electrical charges. Models of different configurations were
simulated for 100 ps at 310 °K after minimization and anneal-
ing. To ensure equilibrated states, the conformations were
collected after the simulations had reached at least 50 ps.
Biological Evaluation of Device Function
Experimental Procedures
The KB cell line is a human epidermoid carcinoma that
overexpresses folate receptors, especially when grown in low
folic acid medium (13). KB cells were purchased from the
American Type Tissue Collection (ATCC; Manassas, VA,
USA) and grown continuously as a monolayer at 37°C, and
5% CO2 in FA deficient RPMI 1640 medium. This medium
was supplemented with penicillin (100 units/mL), streptomy-
cin (100 g/mL), and 10% heat-inactivated FBS, yielding a
final FA concentration approximately that of normal human
serum. About 2 × 105 cells per well were seeded in 12-well
plates the day before the experiments. An hour before initi-
ating an experiment, the cells were washed four times with
FA deficient RPMI 1640 medium, then 1 mL of FA deficient
medium was put in each well. The cells were then incubated
with the folate conjugates under these conditions except for
the competitive antagonism by free FA experiments when
free FA was added in specific concentrations to the media.
After gentle mixing, the cultures were maintained at 37°C,
and the cells were incubated with the folate conjugates for
30 min. For the 0°C experiments, the plates were put on ice
10 min before the addition of the conjugates, and the cells
were maintained at this temperature during the entire experi-
ment. At the end of the incubation period for all experiments,
the medium was aspirated, and three consecutive washes with
2 mL ice-cold PBS were performed. The cells were harvested
by scraping in 0.5 mL 0.1% BSA in PBS. Results were exam-
ined by flow cytometry using a FACS calibur flow cytometer
(Becton Dickinson), and surface and interior localization of
the conjugates was determined using a Bio-Rad MRC 600
confocal microscope (Bio-Rad Laboratories; Hercules, CA,
USA) coupled to a Nikon Diaphot-TMD inverted micro-
scope.
Analysis and Expression of the Results
The double reciprocal plot of the increase in cell fluores-
cence against the concentration of the conjugate was used to
calculate the apparent affinities of the dendrimer-folate con-
jugates for the folate receptor. The results are expressed as
mean values with the corresponding SD.
RESULTS
Modeling of Nanodevices
The conformational structure of the generation 5
PAMAM, fluorescein, folic acid nanodevice (G5-FITC-FA)
was modeled using Molecular Dynamics simulations to test
the effect of the different capping groups (Fig. 1). Local
branch aggregation is observed (Fig. 1a), indicating possible
intermolecular branch interaction. Local branch aggregation
is still observed when the primary surface amine groups were
capped with carboxy groups (Fig. 1c). Both of these molecules
internalized the FA groups in our modeling suggesting a de-
creased potential for receptor interaction. Modeling showed
that capping the surface amines with either 2,3-dihydroxy-
propyl or acetamide groups (yielding neutral surfaces) pro-
duced an overall relaxation of the molecular structure (Fig, 1b
and 1d, respectively) due to the absence of repulsive forces
from charged amines. The model of the 2,3-dihydroxypropyl-
G5-FITC-FA demonstrated greater surface crowding than
the other structures, because the number of hydroxyl groups
is twice that of the acetamide or amine groups. Some of the
FA moieties in this nanodevice also seem to be buried inside
the dendrimer suggesting a reduced likelihood of receptor
interaction. All of the FA moities in the acetamide derivative
appeared to extend away from the surface of the dendrimer,
optimizing the likelihood of receptor interaction.
We measured two radial distances of the FA from the
center of mass of the nanodevice: to the FA-dendrimer link-
ing point and to the center of the pteridinyl ring of a given
folate group (Table I). The mean FA distance of the amine
surfaced G5-FITC-FA is smaller than its radius of gyration,
indicating internalization of the FA and poor accessibility to
the receptor. The mean radius of gyration and mean FA dis-
tance are very similar in the carboxy-G5-FITC-FA, which
increases the accessibility of FA to the receptors. One of the
three FAs is far outside of the radius of gyration imply-
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ing good potential access to FA receptors. The 2,3-
dihydroxypropyl-G5-FITC-FA and acetamide-G5-FITC-FA
nanodevices both show greater mean FA distances than the
radius of gyration of the molecule. A significant portion of
two of the three conjugated FA molecules are partially inter-
nalized in the 2,3-dihydroxypropyl-G5-FITC-FA suggesting
potentially reduced accessibility of the whole FA molecule. In
contrast, only one of three FA moieties in the acetamide-G5-
FITC-FA is partially internalized in the dendrimer, with the
other two FA molecules distributed on the surface.
Evaluation of the Biologic Function of the
Dendrimer-Folate Nanodevices
Nontargeted Binding of Amine-Surfaced Nanodevices
G5-FITC-FA nanodevices bound poorly to KB cells
showing minimal uptake at a 30 nM concentration only after
long incubation times (4 h or greater). Control G5-FITC,
lacking FA, gave similar uptake suggesting that the binding of
both dendrimers was not the result of specific binding to the
folate receptors. The presence of a high concentration (1M)
of free FA in the medium failed to block binding of the G5-
FITC-FA also suggesting nontargeted binding to the cells.
Targeted Uptake of Dendrimers with Modified Surfaces
The binding of carboxy-G5-FITC-FA, 2,3-dihydroxy-
propyl-G5-FITC-FA, and acetamide-G5-FITC-FA nanode-
vices to KB cells was efficient and rapid occurring at a device
threshold concentration of 10 nM after only 30 m at 37°C
(Fig. 2a and 2b). Under these conditions, control nanodevices
with identical surface modifications but without folate did not
bind to KB cells. While all surface modifications with folate
appeared capable of specifically targeting the cells, marked
differences were apparent between the three surfaces in their
respective ability to bind to KB cells (Fig. 2a and 2c). The
apparent affinity and efficiency of internalization of the car-
boxyl nanodevice was markedly lower than that of the hy-
droxyl and acetamide nanodevices. A maximum increase in
cell fluorescence (approximately 4 times baseline) was ob-
served after the cells were incubated with 30 nM of carboxyl
surfaced nanodevice and actually decreased when the cells
were incubated in higher concentrations. The highest appar-
ent affinity of any complex was observed with the acetamide-
surfaced nanodevice requiring a concentration of only 23 nM
to achieve 50% of maximal binding (Fig. 2c). The binding
capacity was also high, allowing for a 20-fold increase in cell
fluorescence after incubation with 300 nM for 30 min (Fig.
2b). The hydroxyl-surfaced nanodevice showed approxi-
mately half the affinity of the acetamide nanodevice (about 53
nM to achieve 50% of maximal binding), but displayed an
overall binding capacity similar to the acetamide-surfaced de-
vice. We also performed experiments at 0°C to investigate
ATP-dependent internalization through the high-affinity fo-
late receptor, which is inactive at this temperature. The re-
sults (Fig. 2d) were qualitatively similar to those obtained at
37°C (Fig. 2c), but with lower overall increases in cell fluo-
rescence.
The binding seen in the flow cytometry studies was con-
firmed in confocal microscopic images of the cells (Fig. 3a and
3b). The confocal analysis found uptake of the acetamide and
Fig. 1. Configuration of PAMAM G5 dendrimer-FITC-FA conju-
gates after 100 ps molecular dynamics simulation. The underlying G5
PAMAM dendritic structure is in grey; the FITC molecules are rep-
resented in pink; and the folic acid is space filled.
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hydroxyl nanodevices in the KB cells, but no uptake in NIH
3T3 cells, which lack a FA receptor. The acetamide capped
G5-FI-FA material appeared to internalize over a period of
24 h (Fig. 3c). No concentration-dependent increases in up-
take were noted with the carboxyl-surfaced molecule (data
not shown). Control dendrimers with the various surface
modifications (but without FA) also failed to bind to the cells
(Fig 3d).
Competitive Inhibition of Nanodevice Binding and
Internalization by Free FA
Increases in cell fluorescence from the uptake of the
three surface-modified nanodevices were entirely blocked by
the simultaneous presence of free FA in the medium. A free
FA concentration of 25–30 nM reduced the cell fluorescence
from either the acetamide or the hydroxyl nanodevices (at 30
nM) by 50%, suggesting the two had approximately similar
affinity for the folate receptor. Only 40–50% of the three
surface-modified nanodevices could be removed from the sur-
face of cells after three acidic washes (pH 3) applied at the
end of a 30 min incubation period at 0°C. This is in contrast
to free folate, which is completely removed by this technique
in concordance with prior reports.
Intracellular Drug Delivery Using Nanodevices
To evaluate intracellular deliver drug by the nanodevice,
trifunctional devices were designed and synthesized. These
devices had three chemically coupled molecules; a reporting
fluorchrome (FITC), a targeting agent (folic acid), and a che-
motherapeutic (methotrexate) conjugated either through a
nonbiodegradable amide linkage or through an ester linkage
that will hydrolyze at the low pH in the endosome releasing
the methotrexate. Both types of methotrexate triple conju-
gate were internalized into KB cells in vitro as efficiently as
folic acid targeted nanodevices not coupled to drug (Fig. 4a).
Only the nanodevice that was designed to release drug after
folate receptor mediated entry into the cell was cytotoxic,
either acutely or in assays of surviving cell clones (Fig. 4b).
Equimolar concentrations of free methotrexate were 4-fold
less effective in killing the tumor cells than drug conjugated
through ester linkages, while the conjugates with the amide
linkage, and conjugates without drug, were not toxic at any
concentration tested. This suggested improved cytotoxic effi-
ciency due to intracellular drug delivery and release.
DISCUSSION
The delivery of biologically active materials to specific
cells is an important and challenging goal. Current attempts at
achieving delivery have revolved around the use of synthetic
(microsphere) carrier molecules, which are too large to have
access to cells or efficient uptake by cells. Most nanoscale
materials currently used for carrier applications are biologi-
cally derived (e.g., proteins) leading to immunogenicity, are
polydispersed in size or are inconsistent in structural charac-
teristics (polylysine). Dendrimers are one of the first biocom-
patible, synthetic, nanoscaled materials that can be made with
consistent structural characteristics producing a uniform
population of molecules with predictable size and surface
characteristics. These molecules are nonimmunogenic. They
span the size range of proteins—a 1–10 nm diameter and a
1000 to 800,000 kDa molecular weight. Dendrimers are
uniquely suited as carrier structures for drug or bioactive mol-
ecule delivery.
The development of complex nanodevices as delivery
platforms for biomaterials is deceptively complicated and re-
quires significant modification of the polymer carrier. Cou-
pling reactions for targeting, signaling, or therapeutic moi-
eties must be compatible with the previously coupled moi-
eties. Interactions of the polymer backbone with these groups
can alter their function. Merely the coexpression of several
molecules of a given moiety on the polymer surface may lead
to undesirable effects. Aggregation of nanostructures can re-
sult from interactions between different substituted groups
and can inactivate or even precipitate the devices. The devel-
Table I. The Average Values of the Radial Distance of Folic Acid in G5-FITC-Folic Acid Conjugates











Amine 29.5 ± 0.2 22.9 ± 5.3 27.2 ± 1.1 23.4 ± 1.3
37.8 ± 0.8 29.0 ± 1.7
24.6 ± 0.6 16.5 ± 1.4
Carboxyl 34.3 ± 0.2 34.9 ± 4.8 32.4 ± 0.9 30.7 ± 1.6
34.2 ± 1.4 33.1 ± 1.6
46.8 ± 1.5 41.0 ± 2.2
Hydroxyl 21.8 ± 0.1 27.2 ± 2.4 20.6 ± 0.6 30.2 ± 1.1
17.0 ± 0.4 26.9 ± 0.3
25.3 ± 0.5 24.6 ± 0.4
Acetamide 19.8 ± 0.1 26.7 ± 2.8 25.8 ± 1.1 23.4 ± 0.4
18.7 ± 0.8 26.7 ± 0.5
22.3 ± 0.6 30.0 ± 0.7
a Mean values are calculated from simulation time between 50 ps and 100 ps. RG  radius of gyration.
b Mean folic acid distances are calculated from the center of mass to the center of the pteridinyl ring of
folic acid groups.
c Radial distances are calculated from the center of mass.
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opment of multifunctional nanoscale devices is complex and
requires active design and testing.
Our results clearly address a number of these issues and
offer solutions. The covalent attachment of FA, averaging 2
to 3 molecules per dendrimer produced remarkable capability
to target and internalize nanodevices in cells expressing the
folate receptor. Efficient and specific targeting was achieved
only when the primary amines on the surface of the den-
drimer were covalently modified to prevent nonspecific,
charge-based interactions. We were able to define concentra-
tions of FA and FITC that when coupled to the polymer
yielded functional and soluble material. For example, the con-
jugation of FITC to the polymer permitted the detection of
cell binding and uptake using flow cytometry or confocal mi-
croscopy, but the product was only soluable when less than
20% of the amine groups were substituted with FITC. Using
defined dendritic polymers of uniform molecular weight al-
lowed us to design and manufacture a consistently soluble
product within these limitations.
Although the affinity of monomeric FA for the folate
receptor is very high with a Kd of at least 1 nM (19,20), the
concentration required for half the maximal binding of folate
conjugated macromolecules has been reported to be substan-
tially higher suggesting lower affinity. For example, 125I-BSA-
folate conjugate has an apparent affinity of 10 nM (2), despite
having no bulky aromatic groups present in the compound (as
are present in flurochrome dyes). The techniques used in our
study do not permit a precise calculation of the effective af-
finity and avidity of the nanodevices for the folate receptor.
Nevertheless, it appeared that an approximately 23 nM con-
centration of the acetamide nanodevice and 53 nM concen-
tration of the hydroxyl nanodevice was required to reach 50%
of maximal binding. In competition experiments performed at
0°C, the concentration of free FA that reduced by 50% the
amount of association reached by 30 nM of both dendrimer-
folate conjugates was 25 to 30 nM; similar to the concentra-
tion required to compete free FA. This indicates that the
binding of the optimized nanodevice is very efficient. The
difference between the cell-associated nanodevice at 0°C and
at 37°C documents that a significant degree of internalization
of the conjugates occurs before the end of the 30 min incu-
bation period. The acid-resistant binding of the nanodevice
we observed might be due to this type of internalization. Since
it was observed at 0°C, it is also possible that acid resistance
is the result of multiple folate-receptor interactions stabilizing
the binding of the nanodevice to the cell. This hypothesis
remains unresolved because the unique characteristics and
architecture of the dendrimers make it difficult to determine
the interaction between the polymer-bound FA and folate
receptors on cells. Further evaluation using techniques, such
<
Fig. 2. Binding of fluorescent dendrimer-folate conjugates to KB
cells after 30 min incubation. All the experiments were performed at
37°C except Fig. 2d, which was at 4°C. Fig. 2a: cell-associated fluo-
rescence increases with 30 nM of acetamide, hydroxyl, or carboxyl-
surfaced dendrimer-folate conjugates. Fig. 2b: cell-associated fluores-
cence increases with increasing concentrations of acetamide-capped
G5-FITC-FA. Significant background fluorescence was not observed
until the concentration of the nontargeted control complex reached
300 nM. Fig. 2c and Fig. 2d cell-associated fluorescence as a function
of dendrimer-folate concentration is presented for each of the three
types of dendrimer, at 37°C in Fig. 2c and at 4°C in Fig. 2d. Amine-
surfaced dendrimer-folate conjugates did not show binding at 30 min
(data not shown).
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as atomic force microscopy, may better define the exact bind-
ing affinity of these devices.
It is significant that the structural predictions of the mo-
lecular modeling were confirmed by the experimental data
obtained in KB cells. The higher probability for receptor in-
teraction predicted for FA on the acetamide vs. the hydroxyl-
modified dendrimer is confirmed by the lower concentration
of acetimide-surfaced material required for 50% of the maxi-
mum association and by the relatively greater binding of the
acetamide vs. the hydroxyl and carboxyl conjugates at
equimolar concentrations. Examinations of a range of designs
for nanodevices guided by molecular modeling has the poten-
tial to rapidly improve performance characteristics.
The tendency of the carboxyl conjugate to aggregate
might explain the limited cell fluorescence observed reaching
a plateau at four-fold over baseline, at concentrations above
30 nM (Fig. 2c and 2d). It is possible that aggregation of
higher concentrations of the polymer prevented further bind-
ing to and uptake into the cells. This is especially important
Fig. 4. Studies examining intracellular drug delivery with nanodevice.
Flow cytometry data Fig. 4a show that the devices are readily taken
into cells regardless of drug conjugate. A comparison of the efficiency
in killing tumor cells Fig.4b of ester or ester conjugated drug and free
methotrexate. The dendrimer- delivered drug is many times more
efficient at killing the KB cells than methotrexate alone.
<
Fig. 3. Confocal and fluorescence microscopic images of cells treated
with acetamide-G5-FITC-FA. Each panel shows corresponding light
(left) and fluorescent (right) images of the same slide. The top four
show KB cells, and the bottom one shows NIH 3T3 cells that do not
express the folate receptor. The upper three panels demonstrate the
binding and uptake of folic acid dendrimer conjugates at 30 min,
Fig. 3a; 6 h, Fig. 3b; and 24 h, Fig. 3c. As a control KB cells were
incubated with fluorescent acetamide-G5-FITC not conjugated to fo-
lic acid Fig. 3d. The top three panels clearly demonstrate the binding
and internalization of the nanodevice over 24 h.
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given the much greater increases in cell-associated material
observed with higher concentrations of the acetamide and
hydroxyl-surfaced nanodevices, which provide functional ad-
vantages for these molecules.
Intracellular drug delivery has advantages over simple
diffusion of drug into cells. Our drug internalizing devices
were four-fold more efficient at inducing cytotoxicity in KB
cells than free drug. This did not appear to be the result of
polymer-related cytotoxicity, as the polymer controls were
not cytotoxic. It is possible that releasing the drug within the
cell will target it to the organelle where it is active. Since
methotrexate directly competes with folic acid, delivering it
through these receptors may be especially useful in this re-
gard. Another possibility is that this type of delivery may
overcome the effect of the multidrug resistance channel. The
KB cells used in this study have an active multidrug resistance
channel (21), so the cytotoxicity seen is especially significant.
This type of channel is most efficient for drugs diffusing
across the membrane and delivering drug deep within the cell
may prevent it from being rapidly pumped out, and this pos-
sibility deserves further study.
This material has potential to target tumors in vivo be-
cause of its small size targeted by a high avidity multivalent
ligand. It is likely that other delivery devices would not
readily gain access to tumors from the vasculature due to their
diameters between 40 to 100 nm, which is too big to trans-
verse vascular pores (22) or a tendency to aggregate. This
device is the same size as a small serum protein and therefore
can pass through pores in the vasculature and infuse tumor
cells directly (23). The rapid and specific binding and inter-
nalization of the device within tumor cells suggests the ability
of this delivery system to transport biosensors, drugs, genetic
material, and imaging agents into specific cells. Studies on this
are warranted in appropriate animal models.
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